Skip to main content
Clinical Trials/NCT02691234
NCT02691234
Unknown
Phase 1

Safety and Efficacy of Low Intensity Shockwave Therapy in Treating Diabetic Foot Ulcers

Hadassah Medical Organization0 sites30 target enrollmentApril 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Diabetic Foot Ulcers
Sponsor
Hadassah Medical Organization
Enrollment
30
Primary Endpoint
To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.
Last Updated
10 years ago

Overview

Brief Summary

Low intensity shockwaves for treating diabetic foot ulcers (DFUs) have been in evaluation for the past 5 years. Many researchers showed the effectiveness of Low intensity shockwaves of in accelerating the healing rate of non-ischemic chronic DFUs. Wang et al. showed, the use of Low intensity shockwaves on DFUs, significantly improved topical blood flow perfusion rate, increased cell proliferation and cell activity and decreased cell apoptosis.

The present study deals with the effect of low intensity shockwaves on DFUs. Shockwave treatment will be done together with the standard conventional treatment for DFUs, compared to a control group who will receive the same conventional standard of care.

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
April 2017
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Chronic non-healing diabetic foot ulcers for more than 2 months.
  • Age 18-80 years
  • Ankle Brachial Index (ABI) ≥0.6
  • Diabetic Foot Ulcer with the long diameter of ≤7cm and a short diameter of ≥1cm
  • The target ulcer is up to Wagner's grade 3
  • Albumin level ≥25g/L
  • Hemoglobin level ≥90g/L
  • Estimated Glomerular Filtration Rate (eGFR) ≥30ml/min/1.73m2
  • The patient agrees to comply with study protocol requirements, including the shockwave procedure, self-care of the ulcer (dressings, orthotics etc.) and all follow-up visit requirements

Exclusion Criteria

  • Pregnancy or lactation
  • The long diameter of the target ulcer is \>7cm and the short diameter is \<1cm
  • The target ulcer is of Wagner's grade 4 or above
  • Severe Hypoalbuminemia \<25g/L
  • Severe anemia, Hemoglobin level \<90g/L
  • eGFR \<30ml/min/1.73m2
  • Patients suffering from acute Charcot foot
  • Severe edema of the treated limb
  • Patient with present malignancy or past malignancy in the treated area
  • Systemic chemotherapy/ radiation treatment within the last 6 months

Outcomes

Primary Outcomes

To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.

Time Frame: four weeks

Similar Trials